Employees 2013: 69,000
Employees 2012: 91,000
% Change: -24.18
Revenues 2013: $21.8 billion
Revenues per employee 2013: $315,942

Abbott ($ABT) kicked off 2013 with a highly anticipated spinoff of its pharma unit into AbbVie ($ABBV). The restructuring accounts for the significant employee reduction for the year and explains why Abbott leads the list in percentage decline. By letting go of Humira, Abbott's blockbuster anti-inflammatory drug, the company took a gamble that CEO Miles White was pushing for since 2012.

The spinoff allowed Abbott to invest all its energy and resources into several key areas: diagnostics, nutritionals, branded generic pharmaceuticals and medical devices, an area that also saw cuts in 2013 to offset falling sales of some last-gen products. The tighter focus ostensibly made Abbott a safer bet for investors looking for a steadily growing company.

But Abbott wasn't done shaving its pharma business. It recently agreed to sell Mylan ($MYL) its portfolio of older drugs sold outside of the U.S., but in established markets. The $5.3 billion stock swap gives Abbott a 21% interest in a new, Netherlands-based company that Mylan will form to take advantage of a lower tax rate. Much of Abbott's recent success has been strategically found in emerging global markets instead.

Abbott has also targeted the little people, with its largest profit margin coming from infant formula sales through its highly successful nutrition department. The unit brought in $6.47 billion in 2013, despite a significant recall the company suffered in China.

For more:
Mylan beefs up outside the U.S. with $5.3B deal for Abbott drug business
Abbott lops off another 450 jobs at stent plant


Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

The agency has granted Tecentriq a priority review in previously untreated NSCLC, setting up the Roche drug for an approval decision by June 19.

Warren Buffett's Berkshire Hathaway has built a $192 million stake in Biogen, a risky investment considering aducanumab's uncertain future.